Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06727773 · ClinicalTrials.gov registry record · Phase 2

Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer

A Phase 2 study of Breast Cancer and Cognitive Impairment, sponsored by UNC Lineberger Comprehensive Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
90
Enrollment target
1
Study location

NCT06727773 is a Phase 2 study of Breast Cancer and Cognitive Impairment that is actively recruiting participants, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 90 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06727773, a Phase 2 study of Breast Cancer and Cognitive Impairment, is actively recruiting participants, sponsored by UNC Lineberger Comprehensive Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
90 participants
Enrollment target
1
Study location

Study Summary

This randomized, placebo-controlled trial aims to assess the feasibility, acceptability, and preliminary efficacy of memantine and the University of Carolina (UNC)'s Get Real \& Heel cancer exercise program (MEM+EX) in addressing cancer-related cognitive impairment (CRCI) and underlying CRCI biomarkers. Ninety stage I-III breast cancer patients with mild cognitive difficulties during chemotherapy will be randomized into three groups: MEM+EX, memantine, or placebo. The study will evaluate recruitment, retention, adherence, acceptability, cognitive function, brain-derived neurotrophic factor (BDNF), inflammatory markers, and frailty at multiple time points.

Conditions Studied

Breast Cancer Cognitive Impairment Cognitive Decline Cognitive Change Breast Cancer Stage II Breast Cancer Stage III Breast Cancer Stage I Locally Advanced Breast Cancer

Interventions

  • OTHER Exercise Intervention
  • DRUG Memantine
  • DRUG Placebo medication
  • OTHER Exercise Control

Study Locations (1)

North Carolina

  • Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill - Chapel Hill

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2025-05-07
Est. Completion 2028-10-31
Phase Phase 2

Sponsor

UNC Lineberger Comprehensive Cancer Center

366 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06727773

The ClinicalTrials.gov registry entry for NCT06727773 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.

The record links to 8 conditions, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Exercise Intervention is the first listed.

NCT06727773 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT06727773 about?

NCT06727773 is a clinical study titled "Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer". This randomized, placebo-controlled trial aims to assess the feasibility, acceptability, and preliminary efficacy of memantine and the University of Carolina (UNC)'s Get Real \& Heel cancer exercise program (MEM+EX) in addressing cancer-related cognitive impairment (CRCI) and underlying CRCI biomark...

What is the current status of trial NCT06727773?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2025-05-07. Estimated completion is 2028-10-31.

What conditions does trial NCT06727773 study?

This clinical trial studies the following conditions: Breast Cancer, Cognitive Impairment, Cognitive Decline, Cognitive Change, Breast Cancer Stage II.

What interventions are being tested in trial NCT06727773?

The interventions under investigation include: Exercise Intervention (OTHER), Memantine (DRUG), Placebo medication (DRUG), Exercise Control (OTHER).

Who is sponsoring clinical trial NCT06727773?

This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06727773 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Cognitive Impairment

All registered trials for this condition

North Carolina

All trials with a study site in North Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.